AZD1208 is a potent and selective inhibitor of PIM (proviral integration site for moloney murine leukemia virus) kinases, which play a role in cell survival, proliferation, and apoptosis resistance. It has been primarily investigated for its potential in oncology, particularly in hematological malignancies such as acute myeloid leukemia (AML) and other cancers where PIM kinase signaling is overactive. By blocking PIM kinase activity, AZD1208 disrupts downstream signaling pathways that support tumor growth and survival, leading to reduced cancer cell proliferation and induction of apoptosis. The compound has served as a tool in preclinical research to understand the biological role of PIM kinases in cancer progression and therapy resistance. It has shown synergistic effects when combined with other anticancer agents, such as PI3K or MEK inhibitors, suggesting potential for use in combination therapies. Although development for clinical use has been limited due to challenges such as pharmacokinetics and toxicity, AZD1208 remains a valuable compound for studying PIM kinase inhibition and its therapeutic implications in cancer.